PFE Jan 2026 17.500 call
| Previous close | 12.25 |
| Open | 12.25 |
| Bid | 11.85 |
| Ask | 12.05 |
| Strike | 17.50 |
| Expiry date | 2026-01-16 |
| Day's range | 12.25 - 12.25 |
| Contract range | N/A |
| Volume | |
| Open interest | 724 |
Business WirePfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia
NEW YORK, September 14, 2024--Pfizer Inc. (NYSE: PFE) today announced its Phase 2 study of ponsegromab, a monoclonal antibody directed against growth differentiation factor-15 (GDF-15), met its primary endpoint of change from baseline in body weight compared to placebo in people with cancer cachexia and elevated levels of GDF-15. Cachexia is a common, life-threatening wasting condition that can significantly impact quality of life in affected patients with cancer.ii,iii Results will be presented
Business WirePfizer’s BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
NEW YORK, September 14, 2024--Pfizer Inc. (NYSE: PFE) today announced longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial evaluating the efficacy and safety of BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib) for patients with BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC). After an additional 18 months of follow-up, the objective response rate (ORR) and the median duration of response (DoR) as assessed by independent radiology revie
Insider MonkeyPfizer Inc. (PFE): A Bull Case Theory
We came across a bullish thesis on Pfizer Inc. (PFE) on gurufocus by Akim Guerreiro. In this article we will summarize the bulls’ thesis on PFE. Pfizer Inc. share was trading at $29.16 as of Sept 12th. Pfizer Inc. (PFE) represents an attractive investment opportunity despite its poor stock performance in 2023, highlighted by the company’s substantial […]
